There are currently 279 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas, California +13 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Adapting the Tumor Board Model for Mental Illness and Cancer
NCT05837598
Recruiting
This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Mass General/North Shore Center for Outpatient Care, Danvers, Massachusetts
Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
Register for Updates
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? 2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: UCLA Health (Santa Monica Cancer Care), Santa Monica, California +5 locations
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates
Multi-Cancer Early Detection (MCED) of Firefighters
NCT05780957
Recruiting
This study is an an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2023
Locations: Vincere Cancer Center, Scottsdale, Arizona
Conditions: Cancer
Register for Updates
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
NCT05338073
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic, Rochester, Minnesota +2 locations
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Register for Updates
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: City of Hope, Duarte, California +9 locations
Conditions: Cancer
Register for Updates
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
NCT02070328
Recruiting
Proton therapy is a limited medical resource that is more expensive than conventional x-ray therapy. To correctly measure the success of proton therapy in treating different conditions, it is important to check a patient's health status after their treatment is finished. Checking on the progress of patients over many years (called long-term follow-up) is needed because the long-term effects of proton therapy are not well known.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2023
Locations: Ackerman Cancer Center, Jacksonville, Florida +2 locations
Conditions: Cancer
Register for Updates
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
NCT05693831
Recruiting
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications. The primary objective of this study is to survey phy... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/20/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Cancer, Relapsed Cancer, Refractory Cancer
Register for Updates
Universal Germline Testing in the Community
NCT05416710
Recruiting
This study seeks to enroll participants who have a diagnosis of a solid tumor cancer and are willing to undergo germline genetic testing for cancer risk. At baseline, patients will be asked to provide 2 types of blood samples: 1 tube for clinical genetic testing and 2 tubes for future research use. A tumor sample from a previous resection or biopsy will also be obtained and sent to the sponsor. The clinician will be asked to provide relevant medical history and demographic information to the spo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2022
Locations: Carolina Blood and Cancer Care Associates, PA', Rock Hill, South Carolina
Conditions: Cancer, Solid Tumor, Solid Tumor, Adult
Register for Updates
Collection and Distribution of Biospecimens for Novel Research Uses
NCT03848962
Recruiting
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have... Read More
Gender:
ALL
Ages:
Between 1 month and 89 years
Trial Updated:
11/08/2022
Locations: iSpecimen, Huntsville, Alabama +1 locations
Conditions: Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Register for Updates
Phase I Human Analytics (HALO) Study
NCT05423860
Recruiting
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders. Additionally, the stud... Read More
Gender:
MALE
Ages:
Between 45 years and 90 years
Trial Updated:
10/12/2022
Locations: Desert Medical Imaging, Indian Wells, California
Conditions: Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
Register for Updates
A Study in Patients With Advanced Cancers
NCT05320588
Recruiting
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2022
Locations: NEXT Oncology Austin, Austin, Texas +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Register for Updates